InventisBio Reports Positive Phase 2 Results for D-2570 in Moderate to Severe Plaque Psoriasis

In a recent announcement on December 3, 2024, InventisBio Co., Ltd. shared compelling results from their Phase 2 clinical trial of D-2570, an oral selective TYK2 kinase inhibitor, aimed at treating patients with moderate to severe plaque psoriasis. This trial, which was randomized, multicenter, double-blind, and placebo-controlled, illustrated significant improvements in skin clearance for patients using D-2570 while maintaining a positive safety profile.

The trial's findings were particularly noteworthy, with over 85% of patients across all D-2570 dose groups achieving a 75% or greater improvement in the Psoriasis Area and Severity Index (PASI 75) by the 12th week, compared to only 12.5% in the placebo group. Additionally, 50% of those on the highest dose of D-2570 achieved complete skin clearance (PASI 100) by the same week, a stark contrast to the 2.5% in the placebo group. Significant results were also seen in PASI 90 and static Physician's Global Assessment (sPGA) 0/1 responses, with the high-dose group showing 77.5% and 87.5% respectively, compared to 5.0% and 20% in the placebo group.

The study involved 161 patients who were randomized to receive varying doses of D-2570 or a placebo. The primary endpoint, PASI 75, was reached by a substantially greater number of patients in all D-2570 dose groups compared to the placebo group, with statistical significance (p<0.001). The drug's effectiveness was evident across secondary endpoints as well, including PASI 90, PASI 100, and sPGA 0/1.

Regarding safety, D-2570 was well-tolerated with no serious adverse events reported. Most adverse events were categorized as mild to moderate (CTCAE Grade 1 or 2), with no new safety concerns emerging. The safety profile was consistent with other TYK2 inhibitors that have either been approved or are undergoing clinical development.

Dr. Ling Zhang, Chief Medical Officer of InventisBio, highlighted the significance of these findings, stating that moderate to severe plaque psoriasis significantly impacts patients' physical health and quality of life. She noted that D-2570 has shown transformative potential, with efficacy comparable to leading biologics and IL-23 targeted peptide therapies, while also providing the convenience of oral administration. Dr. Zhang emphasized InventisBio's commitment to advancing D-2570's development to offer innovative and effective treatment options for patients affected by autoimmune diseases such as psoriasis and inflammatory bowel diseases.

The detailed data from this Phase 2 trial is scheduled to be presented at upcoming scientific conferences, providing further insights into D-2570’s potential as a treatment for autoimmune conditions.

D-2570 is an oral TYK2 JH2 pseudokinase domain inhibitor, developed for autoimmune diseases like psoriasis. It works by selectively targeting TYK2, thereby modulating key cytokine signaling pathways involved in autoimmune inflammation. This approach presents a potential alternative to biologic therapies, which are commonly used in treating such conditions.

InventisBio Co., Ltd. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies for treating cancer, metabolic, and autoimmune diseases. The company's mission is to address unmet medical needs through a robust research pipeline, aiming to provide transformative treatments to patients globally.